GET DAILY SIGNALSAutonomix Medical (AMIX) Shares Drop -51% in 30 Days as Dilution Pressures Intensify
Key Takeaways
- AMIX shares fell roughly 51% over the last 30 days, closing near $1.48 after trading around $3.01 in mid-October.
- The decline extends a sustained multi-month downtrend, with the stock down approximately 78% over the last quarter.
- Persistent dilution, including warrant exercises, rapid share-count growth, and shareholder approval of another reverse stock split, is the central pressure on the stock.
- As a pre-revenue, development-stage medical device company, Autonomix continues to record net losses and burn cash, keeping financing concerns front and center.
- Positive regulatory and intellectual-property milestones, including favorable FDA 510(k) feedback and new patents, have been overshadowed by balance-sheet concerns.
- For deeper detail on this ticker, explore its dedicated Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading strategies approach fast-moving names like AMIX.
Autonomix Medical (AMIX) Company Overview and Market Position
Autonomix Medical, Inc. is a development-stage medical device company focused on sensing and treating disorders of the nervous system. Its core platform combines a catheter-based, microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system, with an approach the company describes as "sense, treat, and verify." The initial development focus is on patients with pancreatic cancer, with potential applications extending to chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
Founded in 2014 and headquartered in The Woodlands, Texas, the company went public on Nasdaq in early 2024. Because Autonomix generates no meaningful revenue, investors follow the stock primarily for its clinical and regulatory progress, its expanding patent estate, and its ability to fund operations through development. Those dynamics make the shares highly sensitive to financing news and regulatory milestones alike. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Autonomix Medical (AMIX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AMIX declined roughly 51%. Shares traded near $3.01 in mid-October and closed at $1.48 on November 11, with the pullback marked by elevated volatility and episodes of unusually heavy trading volume. The move reflects more than a single-session event; it is part of a broader slide that has pushed the stock toward the lower end of its 52-week range of approximately $1.42 to $32.55.
The last quarter tells the same story on a larger scale. From a level near $7.50 in mid-August, the stock has fallen roughly 78% to recent prices. Technical measures underscore the weakness: the shares trade well below their 50-day moving average, and momentum indicators such as the relative strength index have signaled oversold conditions without yet producing a durable rebound.
What Drove AMIX Stock Price in the Last 30 Days
The dominant driver over the past month has been dilution, not operations. Shareholders approved a reverse stock split at a ratio between 1-for-2 and 1-for-25, along with an amendment to the company's equity incentive plan to increase authorized shares. Combined with earlier warrant exercises, the company's outstanding share count has expanded sharply, weighing on the per-share value even as management works to narrow losses.
The company's fiscal second-quarter filing, covering the period ended September 30, 2026, reinforced the financing picture. Autonomix reported a quarterly net loss of roughly $3.1 million and a six-month net loss of about $5.9 million, with no revenue. While the losses narrowed year over year and cash on hand improved, the accumulated deficit remains substantial, and the company has disclosed going-concern considerations in its filings.
Notably, several genuinely positive developments arrived during the window: the company announced favorable FDA pre-submission feedback supporting a 510(k) regulatory pathway, and it reported new patent issuances in the United States, Canada, and Europe. However, these milestones have not offset the financing overhang, and the stock's move reflects investors repricing that risk amid penny-stock-level volatility.
What Drove AMIX Stock Performance Over the Last Quarter
The quarterly decline is best understood as a cumulative dilution story. The company completed a 1-for-21 reverse stock split in June 2026 and has since relied on repeated equity-linked financings, including a warrant-inducement transaction that raised gross proceeds in the millions of dollars. These raises have grown the share count by a triple-digit percentage year over year while providing the cash needed to fund development.
Against this backdrop, the company's regulatory progress has been real but incremental. The FDA's positive feedback on a potential Class II 510(k) pathway is a meaningful de-risking event, and management has outlined a target of approximately 15 months to potential U.S. clearance for its standalone sensing platform. The challenge is arithmetic: a pre-revenue company burning roughly $2.7 million per quarter must continue accessing capital, and each round of funding has so far been dilutive. Investors have responded by demanding a lower price for exposure to that roadmap. From what I see, this arithmetic remains the key variable to track.
AMIX Stock Forecast Drivers: What Investors Should Watch Next
Several factors will likely shape AMIX going forward. The company's next earnings report and management commentary on cash runway, burn rate, and financing plans will be closely watched, as will any implementation details of the newly approved reverse stock split and its effect on Nasdaq listing compliance. Progress toward the 510(k) submission for the standalone sensing platform and any updates to the clearance timeline represent the primary clinical-regulatory catalysts.
On the financial side, investors should monitor the pace of future capital raises, warrant activity, and changes to the share count, since these have been the dominant drivers of the stock's recent decline. Macroeconomic conditions affecting small-cap and pre-revenue healthcare names may also influence sentiment. As always, these are informational factors to monitor, not a basis for any specific investment decision. I'm watching this closely as the next earnings release approaches.
Exploring AI Tools for Trading Insights
In my analysis of volatile names like AMIX, I often turn to Tickeron’s AI Trading Bots to see how systematic strategies respond to momentum shifts and dilution-driven moves. These tools help compare different approaches across market conditions and offer a rules-based view that complements traditional fundamental review. I find the Trending AI Robots section particularly useful for gaining perspective on event-driven stocks without relying solely on manual charting.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AMIX in upward trend: price may jump up because it broke its lower Bollinger Band on October 26, 2026
AMIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 26 cases where AMIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for AMIX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Moving Average Convergence Divergence (MACD) for AMIX just turned positive on November 09, 2026. Looking at past instances where AMIX's MACD turned positive, the stock continued to rise in 17 of 20 cases over the following month. The odds of a continued upward trend are 85%.
Following a +21.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMIX advanced for three days, in 77 of 106 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AMIX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.942) is normal, around the industry mean (4.142). P/E Ratio (-0.049) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. AMIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement